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Key messages 
What is already known about this subject?
 ► Preclinical studies of human osteoarthritis 
(OA) and mouse models suggested that 
interleukin-1α (IL-1α) and IL-1β were potential 
mediators of synovitis, cartilage damage, and 
bone loss in patients with erosive hand OA 
(HOA). Lutikizumab is a dual variable domain 
immunoglobulin (DVD-Ig) that binds and 
neutralises both IL-1α and IL-1β.
What does this study add?
 ► In this phase 2a, randomised, double-blind 
study in patients with erosive HOA, treatment 
with lutikizumab, versus placebo, did not result 
in significantly better improvements in hand 
joint pain, despite adequate neutralization of 
IL-1α and IL-1β.
 ► Besides hand pain, other symptomatic, 
functional, and structural efficacy endpoints 
were not significantly different for erosive 
HOA patients treated with lutikizumab versus 
placebo.
 ► Injection site reactions, neutropenia, and 
discontinuations because of AEs were more 
frequent with lutikizumab compared with 
placebo.
How might this impact on clinical practice?
 ► Targeting IL-1 may not be effective for the 
treatment of erosive HOA.
AbsTrACT
Objective To assess the efficacy, safety, 
pharmacokinetics and pharmacodynamics of the 
anti-interleukin (il)-1α/β dual variable domain 
immunoglobulin lutikizumab (aBT-981) in erosive hand 
osteoarthritis (HOa).
Methods Patients with ≥1 erosive and ≥3 tender and/
or swollen hand joints were randomised to placebo or 
lutikizumab 200 mg subcutaneously every 2 weeks for 24 
weeks. The primary endpoint was change in australian/
Canadian Osteoarthritis Hand index (aUsCan) pain 
subdomain score from baseline to 16 weeks. at baseline 
and week 26, subjects had bilateral hand radiographs 
and MRi of the hand with the greatest number of 
baseline tender and/or swollen joints. Continuous 
endpoints were assessed using analysis of covariance 
models, with treatment and country as main factors and 
baseline measurements as covariates.
results Of 132 randomised subjects, 1 received no 
study drug and 110 completed the study (placebo, 61/67 
(91%); lutikizumab, 49/64 (77%)). aUsCan pain was not 
different among subjects treated with lutikizumab versus 
placebo at week 16 (least squares mean difference, 
1.5 (95% Ci –1.9 to 5.0)). Other clinical and imaging 
endpoints were not different between lutikizumab 
and placebo. lutikizumab significantly decreased 
serum high-sensitivity C reactive protein levels, il-1α 
and il-1β levels, and blood neutrophils. lutikizumab 
pharmacokinetics were consistent with phase i studies 
and not affected by antidrug antibodies. injection site 
reactions and neutropaenia were more common in the 
lutikizumab group; discontinuations because of adverse 
events occurred more frequently with lutikizumab (4/64) 
versus placebo (1/67).
Conclusion Despite adequate blockade of il-1, 
lutikizumab did not improve pain or imaging outcomes in 
erosive HOa compared with placebo.
InTrOduCTIOn
Hand osteoarthritis (HOA) is highly prevalent, espe-
cially among women and the elderly.1 2 Erosive HOA, 
characterised by pain, swelling, interphalangeal 
joint inflammation and central erosions,3 4 can result 
in substantial disability.5–7 Treatments are limited8 
to topical and oral non-steroidal anti-inflammatory 
drugs (NSAIDs) to relieve pain9; there are no 
disease-modifying OA drugs that prevent structural 
damage.8 9 Antitumour necrosis factor (anti-TNF) 
therapies in patients with erosive HOA failed to 
demonstrate significant pain relief but did slow 
structural progression of inflamed joints.10 11 A 
randomised, placebo-controlled study (Hydroxy-
chloroquine Effectiveness in Reducing symptoms of 
hand Osteoarthritis (HERO)) showed no significant 
symptomatic or radiographic efficacy for hydroxy-
chloroquine in patients with severe HOA.12 The 
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efficacy of intra-articular steroid injections has been equivocal in 
patients with HOA.13
Inflammatory cytokines such as interleukin-1 (IL-1) may be 
involved in the pathogenesis of OA.14 15 IL-1α and IL-1β bind 
to the IL-1 type 1 receptor (IL-1R1), leading to the produc-
tion of proinflammatory molecules, proteases and other medi-
ators,16 17 which result in joint pain, inflammation and cartilage 
destruction.15 IL-1 is also present in the bone,18 where it plays 
an important role in bone resorption.18–20 In a rabbit model, 
production of transfected exogenous IL-1 receptor antagonist 
(IL-1Ra) reduced the severity of induced knee OA lesions.21 In 
clinical trials, an IL-1Ra drug (anakinra)22 and an antibody (AMG 
108) that blocks the IL-1R123 were generally well tolerated, but 
did not significantly improve symptoms in patients with knee 
OA. However, in contrast to knee OA,24 erosive HOA is asso-
ciated with an IL-1β gene polymorphism,25 and in a case series 
(n=3) anakinra markedly improved pain in patients with erosive 
HOA,26 implying that inhibition of IL-1 might be beneficial.
Lutikizumab (ABT-981), a novel human dual variable 
domain immunoglobulin (DVD-Ig), simultaneously binds and 
inhibits IL-1α and IL-1β without interfering with other human 
IL-1 family members including IL-1Ra.27 In a mouse model, 
a mouse anti-IL-1α/β DVD-Ig reduced OA progression28 and 
increased the threshold for evoked pain29 more than inhi-
bition of either IL-1α or IL-1β alone. In a phase I multiple 
ascending-dose study in subjects with knee OA, lutikizumab 
was generally well tolerated and associated with expected 
pharmacodynamic effects, including reductions in neutrophils, 
high-sensitivity C reactive protein (hsCRP) and reductions in 
markers of synovitis (matrix metalloproteinase (MMP)-de-
graded collagen type III (C3M), MMP-generated fragment of 
CRP (CRPM) and MMP-degraded collagen type 1 (C1M)).30 
The objective of the current study was to determine the clin-
ical and structural efficacy, safety, pharmacokinetics and phar-
macodynamics of lutikizumab in patients with erosive HOA.
MeTHOds
study design
The design of this phase IIa, randomised, double-blind, 
placebo-controlled, parallel-group study (NCT02384538; 
EudraCT 2014-001096-31) in patients with erosive HOA 
(online supplementary figure 1) was based on the recommen-
dations of an Osteoarthritis Research Society International 
(OARSI) task force.31 All subjects provided informed consent. 
After a screening and washout period of approximately 45 
days, subjects were randomised 1:1 to placebo or lutikizumab 
200 mg subcutaneously every 2 weeks for 24 weeks (13 injec-
tions) using stratification by country (online supplementary 
methods).
subjects
Adult patients 35–80 years diagnosed with HOA and fulfilling 
the American College of Rheumatology criteria32 were eligible. 
Key inclusion criteria included active inflammation (ie, ≥3 
tender and/or swollen interphalangeal joints), subject-rated hand 
pain ≥6 (11-point Numeric Rating Scale (NRS-11), 0–10), and 
radiographic evidence of ≥1 interphalangeal joint defined by 
Verbruggen et al33 as erosive (E; subchondral plate eroded) or 
erosive/remodelling (E/R; new irregular sclerotic subchondral 
plates with intervening space in a part of the joint). Radiographs 
were centrally scored by CP for eligibility. Subjects had to have 
discontinued use of analgesics, NSAIDs and nutraceuticals 
(online supplementary methods).
Key exclusion criteria included previous anti-IL-1 treatment; 
corticosteroid use within 1 month before screening; immunosup-
pressive therapy within 1 month (biologic) or 3 months (conven-
tional) or 5 half-lives, whichever was longer, before beginning 
the study drug; colchicine within 1 month before beginning the 
study drug; diagnosis of fibromyalgia, inflammatory arthritis, 
gout, pseudogout, secondary OA, psoriatic arthritis or psoriasis; 
active or latent, untreated tuberculosis; and evidence of prema-
lignant dysplasia or history of malignancy within 5 years, except 
successfully treated non-metastatic cutaneous squamous cell, 
basal cell carcinoma or localised carcinoma in situ of the cervix. 
Patients with a positive hepatitis A, B or C virus and HIV test 
were excluded with evidence of active infection (vs past infec-
tion) or history of HIV.
efficacy
The primary endpoint was change from baseline to 16 weeks 
in the Australian/Canadian Osteoarthritis Hand Index score 
(AUSCAN V.3.1; NRS-11, range 0–50 pain subdomain score) 
(online supplementary methods).34 A key secondary endpoint 
was change from baseline to 26 weeks in AUSCAN function 
subdomain score (NRS-11, range 0–90).34 Key exploratory 
endpoints included change from baseline to 26 weeks in swollen 
and tender joint counts (each totalling 0–30 for metacarpopha-
langeal, proximal interphalangeal, distal interphalangeal, first 
interphalangeal and first carpometacarpal joints in both hands), 
structural bone and joint damage by radiography, and synovitis, 
erosive damage, cartilage space loss and bone marrow lesions 
by MRI (online supplementary figure 1, online supplementary 
methods). To assess structural damage, at baseline and week 26, 
subjects had radiography of both hands and MRI of the hand 
with the largest number of tender and/or swollen joints at base-
line (index hand). Radiographs were scored according to a modi-
fied Verbruggen-Veys method,35 the OARSI atlas36 and a modified 
Kellgren-Lawrence Scale.37 38 MRIs were scored using a modified 
Outcome Measures in Rheumatology/Hand Osteoarthritis MRI 
Scoring system (OMERACT/HOAMRIS).39
Central readers, independent of AbbVie, separately scored 
(online supplementary table 1) the radiographs (IKH and FK) 
and the MRIs (CP and Yan Chen, Spire Sciences). Scores of 
the pairs of readers were averaged for both radiographic and 
MRI analyses. However, if an adjudicator score was available 
(online supplementary table 2), it was substituted for both 
radiographic and MRI analyses instead of an average score. 
Discrepancies between readers in radiographic change scores 
above a predefined threshold were adjudicated by a third 
independent reviewer (Gust Verbruggen, Ghent University 
Hospital). The top 10% of discrepancies in scores between 
readers for each feature of the OMERACT/HOAMRIS readings 
were adjudicated by consensus review to identify and correct 
potential input errors. All radiographic and MRI scoring were 
blinded to examination chronology and subject and clinical 
characteristics.
rescue medication
Subjects could take acetaminophen (maximum, 3000 mg/day) as 
rescue medication during the washout period through week 16 
or acetaminophen (maximum, 3000 mg/day) and/or ibuprofen 
(maximum, 1200 mg/day) during weeks 16–26 for breakthrough 
hand pain. Rescue medication was requested to be stopped 48 
hours before clinical outcome assessments at baseline and at each 
biweekly clinic visit.
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Table 1 Demographics and baseline disease characteristics
Characteristics Placebo (n=67) Lutikizumab (n=64)
Age, years, mean±SD 66±7 66±8
Female, n (%) 58 (87) 53 (83)
Race, n (%) 
  White 66 (99) 63 (98)
  Black 1 (1) 0
  Asian 0 1 (2)
BMI, kg/m2, mean±SD 28±5 27±5
OA duration, years 
  Mean±SD 11±8 11±9
  Median (range) 8.5 (0.4–37.5) 7.4 (0.1–34.5)
Prior NSAID use, n (%) 35 (52) 36 (56)
Prior opioids use, n (%) 1 (1) 2 (3)
AUSCAN pain (full scale, 0–50), mean±SD* 39±7 38±6
AUSCAN function (full scale, 0–90), mean±SD* 69±15 71±13
Tender joints, both hands (full scale, 0–30), mean±SD* 12±6 12±7
Swollen joints, both hands (full scale, 0–30), mean±SD* 6±5 6±5
Verbruggen-Veys radiographic erosive joints, both hands (full scale, 0–16), mean±SD† 2±2 3±2
Kellgren-Lawrence score, both hands (full scale, 0–80), mean±SD‡ 42±13 46±13
OARSI JSN, both hands (full scale, 0–58), mean±SD§ 29±10 32±9
OARSI osteophytes, both hands (full scale, 0–58), mean±SD§ 23±11 26±10
HOAMRIS synovitis, index hand (sum score, 0–52.5), mean±SD¶** 11±5 10±4
HOAMRIS erosive damage, index hand (sum score, 0–52.5), mean±SD¶** 18±10 18±9
HOAMRIS BML, index hand (sum score, 0–52.5), mean±SD¶** 7±6 5±5
HOAMRIS cartilage space loss, index hand (sum score, 0–45), mean±SD¶** 14±7 15±7
Joints with synovitis by MRI, index hand (full scale, 0–15), mean±SD¶** 9±3 8±3
ANC, ×109/L, mean±SD 3.8±1.0 4.1±1.6
hsCRP, mg/L 
  Mean±SD 4.1±6.6 4.4±8.0
  Median (range) 1.8 (0.2–44.5) 1.8 (0.3–53.7)
*Placebo: n=66.
†Defined by Verbruggen et al,33 erosive phase+erosive with remodelling phase. Measured in DIP joints 2–5 and PIP joints 2–5.
‡Measured in DIP joints 2–5, PIP joints 2–5, CMC joint of the thumb and IP joint of the thumb.
§Measured in DIP joints 2–5, PIP joints 2–5, MCP joints 1–5, CMC joint of the thumb, IP joint of the thumb and STT joint.
¶Measured in DIP joints 2–5, PIP joints 2–5, MCP joints 1–5, CMC joint of the thumb and IP joint of the thumb.
**Placebo: n=63; lutikizumab: n=59.
STT, scaphotrapeziotrapezoid.ANC, absolute neutrophil count; AUSCAN, Australian/Canadian Osteoarthritis Hand Index; BMI, body mass index; BML, bone marrow lesions; CMC, carpometacarpal; 
DIP, distal interphalangeal; HOAMRIS, Hand Osteoarthritis MRI Scoring system; IP, interphalangeal; JSN, joint space narrowing; MCP, metacarpophalangeal; NSAID, non-steroidal anti-inflammatory 
drug; OA, osteoarthritis; OARSI, Osteoarthritis Research Society International; PIP, proximal interphalangeal; hsCRP, high-sensitivity C reactive protein.
Pharmacokinetics
Blood samples were taken at baseline and throughout the 26 weeks 
to assess lutikizumab levels and antidrug antibody responses to 
lutikizumab (online supplementary methods).
Target engagement and pharmacodynamics
To measure target engagement, IL-1α and IL-1β serum levels 
were measured at baseline and weeks 2 and 4. Pharmacodynamic 
measures included absolute neutrophil counts (ANCs) at baseline 
and every 2 weeks thereafter, serum hsCRP measured at baseline 
and weeks 2, 4, 6, 8, 12, 16, 20 and 26, and serum C1M, C3M, 
CRPM, hyaluronic acid, N-propeptide of collagen IIA (PIIANP), 
and C-terminal telopeptide fragments of type I collagen (CTX-I) 
and urine CTX-II (corrected for urine creatinine) measured at base-
line and weeks 4, 16 and 26 (see online supplementary methods 
for assay methods).
safety
Adverse events (AEs), vital signs, physical examinations and labo-
ratory data were assessed throughout the study (online supplemen-
tary methods).
statistical analyses
Sample size was determined based on the primary efficacy variable, 
change from baseline in AUSCAN pain subdomain score. In published 
HOA and erosive HOA studies, the mean baseline AUSCAN pain 
score ranged from 23 to 33,10 40–42 and the SD of change from base-
line in these scores ranged from 6.7 to 14.10 40 42 43 The sample size 
per group (n=60) was estimated using 10% inflation to account for 
possible dropouts, with 80% power at α=0.05, assuming SD=10 
and based on a two-sided, two-sample t-test for detecting a differ-
ence of 5.4 (20%) between lutikizumab and placebo.
Efficacy was analysed in a modified intent-to-treat population 
comprising randomised subjects who received ≥1 dose of the 
study drug (online supplementary methods). Continuous efficacy 
endpoints were assessed using analysis of covariance models, with 
treatment and country as main factors and baseline measurements 
as covariates. Last observation carried forward (LOCF) imputa-
tion was used for the primary endpoint; observed cases were used 
for other endpoints. Sensitivity analysis using a mixed model that 
assumed randomly missing data revealed only modest differences 
from LOCF, with no impact on the conclusions (data not shown). 
The safety analysis set included subjects who received ≥1 dose of 
the study drug per treatment assignment.
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Figure 1 LS mean change from baseline in AUSCAN pain over time 
(A) and LS mean change from baseline in AUSCAN function over time 
(B). Last observation carried forward imputation was used for analysis 
when values were missing. All comparisons of lutikizumab versus 
placebo were not significant using an analysis of covariance adjusted 
for treatment group and country as factors, and including baseline value 




In this study, 558 patients were screened, 132 randomised and 
131 treated, from 29 April 2015 to 13 July 2016. The most 
common reasons for exclusion were absence of erosions, hand 
pain <6 and laboratory abnormalities (online supplementary 
table 3). Of treated subjects, 61 of 67 (91%) who received 
placebo and 49 of 64 (77%) who received lutikizumab completed 
the study (online supplementary figure 2). In the placebo group, 
1 of 67 (1%) and in the lutikizumab group 4 of 64 (6%) subjects 
discontinued from the study because of AEs. Demographic and 
baseline characteristics were well matched between treatment 
groups (table 1).
efficacy
Pain, function and joint symptoms
The primary efficacy endpoint, least squares (LS) mean (95% CI) 
change from baseline in AUSCAN pain at 16 weeks, was similar 
for placebo (−10.7 (–15.4 to –6.0)) and lutikizumab (−9.2 (−13.8 
to –4.6)) (LS mean difference (95% CI), 1.5 (–1.9 to 5.0); LOCF; 
figure 1A). At 16 weeks, the LS mean (95% CI) change from base-
line in AUSCAN function was −17.2 (–24.9 to –9.4) for placebo 
and −14.6 (–22.1 to –7.1) for lutikizumab (LS mean difference 
(95% CI), 2.5 (−3.2 to 8.3); LOCF; figure 1B). Changes from 
baseline at other time points in AUSCAN pain (figure 1A) and 
function (figure 1B) were similar in subjects treated with lutiki-
zumab compared with placebo. The LS mean change from baseline 
in tender and swollen joint counts at week 26 was similar between 
placebo and lutikizumab (table 2). Other efficacy outcomes (pain, 
stiffness, grip strength and patient-reported outcomes) were also 
not different between the placebo and lutikizumab groups (online 
supplementary table 4).
Imaging
Changes from baseline in radiographic evidence of erosive 
joints (new E, E/R or R phase) and total score, as defined by 
Verbruggen et al and Verbruggen and Veys et al,33 35 were similar 
with lutikizumab and placebo at 26 weeks (figure 2A; table 2). 
Similar results were observed when using the Kellgren-Law-
rence37 and OARSI scoring systems (figure 2A; table 2). MRI 
changes from baseline using the OMERACT/HOAMRIS system 
were not statistically significantly different for lutikizumab 
compared with placebo (figure 2B; table 2).
rescue medication use
Rescue medication use was similar between the treatment groups 
(online supplementary results). In a post-hoc analysis, there was 
no significant impact of disease symptom flares due to discon-
tinuing NSAID use during the screening (washout) period, prior 
to enrolment and randomisation, on the primary endpoint of 
change from baseline to 16 weeks in AUSCAN pain. However, 
among subjects treated with lutikizumab, the magnitude of 
change in the primary endpoint was numerically but not statisti-
cally greater among subjects who were not using NSAIDs at the 
time of screening compared with subjects using NSAIDs at the 
time of screening.
Pharmacokinetics
The mean serum concentrations of lutikizumab collected at the 
week 6 visit or later remained constant, suggesting attainment of 
steady-state lutikizumab serum levels at approximately twofold 
higher than concentrations collected at the week 2 visit, which is 
consistent with the observed half-life and accumulation ratio in 
phase I studies.30 The number of subjects with antilutikizumab 
antibodies at one or more study visits was 4 of 67 (6%) with 
placebo and 9 of 64 (14%) with lutikizumab. The magnitude of 
antilutikizumab antibody response was low and did not appear 
to impact the pharmacokinetic behaviour of lutikizumab.
Target engagement and pharmacodynamics
Lutikizumab treatment compared with placebo was associated 
with significant reductions in serum IL-1α and IL-1β levels, 
although serum levels of both cytokines were low and below the 
limits of quantification for some subjects (online supplementary 
figure 3 and online supplementary table 5). Lutikizumab signifi-
cantly decreased the levels of neutrophils, hsCRP and serum 
C1M compared with placebo (figure 3). Serum C3M, CRPM 
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Table 2 LS mean change from baseline to week 26 in scores for secondary or exploratory efficacy endpoints
endpoint (full scale), mean (95% CI) Placebo Lutikizumab






Tender joints, both hands (0–30) −4.7 (−7.1 to −2.3) n=65 −5.8 (−8.2 to −3.3) n=59 −1.07 (−3.19 to 1.06) 0.32
Swollen joints, both hands (0–30) −1.8 (−3.5 to −0.2) n=65 −2.2 (−3.9 to 0.5) n=59 −0.35 (−1.82 to 1.13) 0.64
Verbruggen-Veys new radiographic erosive joints vs baseline, both hands (0–16)† 0.26 (0.10 to 0.42) n=61 0.18 (0.02 to 0.35) n=52 −0.07 (0.22 to 0.08) 0.33
Kellgren-Lawrence score, both hands (0–80)‡ 0.13 (−0.25 to 0.50) n=61 0.10 (−0.28 to 0.48) n=52 −0.03 (−0.38 to 0.32) 0.87
OARSI JSN, both hands (0–58)§ 0.14 (−0.23 to 0.51) n=61 0.03 (−0.35 to 0.40) n=52 −0.11 (−0.46 to 0.23) 0.51
OARSI osteophytes, both hands (0–58)§ 0.25 (−0.05 to 0.55) n=61 0.14 (−0.17 to 0.45) n=52 −0.11 (−0.39 to 0.17) 0.45
HOAMRIS synovitis, index hand (sum score; 0–52.5)¶ 0.92 (−0.05 to 1.88) n=55 0.85 (−0.16 to 1.86) n=47 −0.07 (−1.01 to 0.87) 0.89
HOAMRIS erosive damage, index hand (sum score; 0–52.5)¶ 0.26 (−1.01 to 1.53) n=55 0.10 (−1.22 to 1.43) n=47 −0.16 (−1.39 to 1.08) 0.80
HOAMRIS BML, index hand (sum score; 0–52.5)¶ 0.11 (−1.61 to 1.38) n=55 0.44 (−0.87 to 1.76) n=48 0.33 (−0.92 to 1.58) 0.60
HOAMRIS cartilage space loss, index hand (0–45)¶ 0.29 (−0.30 to 0.89) n=55 0.46 (−0.16 to 1.09) n=47 0.17 (−0.41 to 0.75) 0.56
Joints with synovitis by MRI, index hand (0–15)¶ 0.46 (−0.20 to 1.11) n=55 0.54 (−0.14 to 1.23) n=47 0.09 (−0.55 to 0.73) 0.79
*P values are from an ANCOVA adjusted for treatment group and country as factors, and including baseline value as a covariate.
†Defined by Verbruggen et al33 as joints that entered the erosive, erosive with remodelling or remodelling phase but were normal, stationary or only starting to lose joint space at baseline. 
Measured in DIP joints 2–5 and PIP joints 2–5.
‡Measured in DIP joints 2–5, PIP joints 2–5, CMC joint of the thumb and IP joint of the thumb.
§Measured in DIP joints 2–5, PIP joints 2–5, MCP joints 1–5, CMC joint of the thumb, IP joint of the thumb and STT joint.
¶Measured in DIP joints 2–5, PIP joints 2–5, MCP joints 1–5, CMC joint of the thumb and IP joint of the thumb.
ANCOVA, analysis of covariance model; BML, bone marrow lesions; CMC, carpometacarpal; DIP, distal interphalangeal; HOAMRIS, Hand Osteoarthritis MRI Scoring system; IP, interphalangeal; JSN, 
joint space narrowing; LS, least squares; MCP, metacarpophalangeal; OARSI, Osteoarthritis Research Society International; PIP, proximal interphalangeal; STT, scaphotrapeziotrapezoid.
and CTX-I were also reduced, although less robustly, in subjects 
treated with lutikizumab compared with placebo (online supple-
mentary table 6). Changes in serum hyaluronic acid, serum 
PIIANP and urine CTX-II (corrected for urine creatinine) were 
similar in the lutikizumab and placebo treatment groups.
safety
Similar proportions of subjects receiving placebo or lutikizumab 
experienced an AE or a serious AE during the study (table 3). 
There were no serious infections during the study. Significantly 
more subjects in the lutikizumab treatment group had injection 
site reactions and neutropaenia (which was not associated with 
an increased rate of infection) compared with the placebo group.
Two subjects who received lutikizumab discontinued study 
treatment because of neutropaenia. One woman (aged 65 
years) had a baseline ANC of 3.07×109/L, which decreased 
to 0.89×109/L after 15 days of treatment, at which time she 
discontinued lutikizumab. Another woman (aged 56 years) had 
a baseline ANC of 2.18×109/L, which decreased to 1.28×109/L 
after 29 days of treatment, at which time she discontinued 
lutikizumab.
There were significant mean reductions from baseline to final 
visit in neutrophil counts (figure 3B), platelet counts, white 
blood cell counts and alkaline phosphatase and increases in 
high-density lipoprotein cholesterol with lutikizumab but not 
placebo (online supplementary table 7). The mean low-density 
lipoprotein cholesterol (LDL-C) levels increased significantly 
from baseline with lutikizumab compared with placebo. Except 
for neutrophil counts and a single triglyceride level that was 
grade 3, the laboratory changes were all grade 1. Grade 2 and 
3 laboratory neutropaenia events occurred in 14% and 5% of 
subjects, respectively, in the lutikizumab group and no subjects 
in the placebo group; there were no grade 4 neutropaenia events 
(table 3).
dIsCussIOn
In the present study, treatment with lutikizumab 200 mg was not 
significantly different from placebo for any efficacy endpoints. 
Lutikizumab had no effect on pain and function. Subjects 
treated with lutikizumab compared with placebo had similar 
radiographic progression by several measures, and the small 
differences were likely not clinically significant. These results 
suggest that targeting IL-1 may be ineffective in erosive HOA, 
in agreement with clinical studies in knee OA22 23 44 and a recent 
mouse study.45
It is unlikely that the lack of a lutikizumab treatment effect was 
due to insufficient levels of inflammation, because study subjects 
had moderate to severe levels of inflammation confirmed by 
tender and/or swollen interphalangeal joints and the presence 
of synovitis on MRI. Furthermore, the absence of a significant 
treatment effect could not be attributed to a lack of drug expo-
sure, as lutikizumab serum levels were stable over time, and anti-
drug antibodies had no notable impact on the pharmacokinetics 
of lutikizumab, although drug levels in the local environment 
of the interphalangeal joints were not assessed. Additionally, 
lutikizumab markedly affected IL-1 levels and pharmacodynamic 
measures associated with inhibition of IL-1 (neutrophil counts 
and hsCRP levels). Furthermore, reductions in neutrophil counts 
and hsCRP were similar to those seen in a study of an IL-1R1 
blocking antibody (AMG 108).23 Finally, data from a dose-range 
finding study of lutikizumab 25, 100 and 200 mg in subjects 
with knee OA strongly suggested that a dose of 200 mg every 2 
weeks produced serum levels of lutikizumab that had maximal 
pharmacodynamic effects.44
Discontinuations due to AEs, neutropaenia and injection site 
reactions were more common with lutikizumab compared with 
placebo. AEs partly explain the higher overall discontinuation 
rate with lutikizumab; however, other unknown factors may 
have had a role. Reductions in neutrophil counts were not asso-
ciated with increased rates of infection. These results are consis-
tent with studies of other IL-1 inhibitors.23 46 47 LDL-C increased 
modestly on average with lutikizumab, as noted with other IL-1 
inhibitors.48 49
Studies with other anti-inflammatory therapies have shown 
mixed results in erosive HOA. At least six studies have reported 
on the efficacy of anti-TNF agents in erosive HOA. In a 1-year, 
randomised, double-blind study (N=90), subcutaneous etaner-
cept was not superior to placebo on a visual analogue pain scale at 
24 weeks.11 However, in patients with more pronounced inflam-
matory symptoms who completed the study, etanercept was 
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Figure 2 Assessment of radiographic endpoints (A) and MRI 
endpoints using the Outcome Measures in Rheumatology Clinical Trials/
Hand Osteoarthritis MRI Scoring system (HOAMRIS) (B). *Defined 
by Verbruggen et al33 as joints that entered the erosive, erosive with 
remodelling or remodelling phase but were normal, stationary or only 
starting to lose joint space at baseline. P values for lutikizumab versus 
placebo are from an analysis of covariance model adjusted for age 
group and Kellgren-Lawrence score as factors, and including baseline 
value as a covariate. BML, bone marrow lesions; JSN, joint space 
narrowing; LS, least squares; OARSI, Osteoarthritis Research Society 
International.
Figure 3 Mean hsCRP levels (A), neutrophil counts (B) and C1M 
levels (C) over time. *P<0.05, †P<0.01, ‡P<0.001, for lutikizumab 
versus placebo, one-way analysis of variance. C1M, metalloproteinase-
degraded type I collagen; hsCRP, high-sensitivity C reactive protein.
Table 3 Safety results
Ae, n (%) Placebo (n=67)
Lutikizumab 
(n=64)
Any AE 59 (88) 58 (91)
Any SAE 2 (3) 2 (3)
AE leading to discontinuation 2 (3) 5 (8)
Neutropaenia leading to discontinuation 0 2 (3)
Death 0 0
Infection 34 (51) 26 (41)
Serious infection 0 0
Injection site reaction 11 (16) 23 (36)
Laboratory abnormality, n (%) 
Neutropaenia (grade 2, 3 or 4) 0 12 (19)
  Grade 2: 1 to <1.5 ×109/L 0 9 (14)
  Grade 3: 0.5 to <1 ×109/L 0 3 (5)
  Grade 4:<0.5 ×109/L 0 0
Hypertriglyceridaemia (grade 3 or 4) 0 1 (2)
  Grade 3: >5.7 to 11.4 mmol/L 0 1 (2)
Grades for laboratory abnormalities were defined by Common Toxicity Criteria.
AE, adverse event; SAE, serious adverse event.
superior compared with placebo on pain and radiographically 
assessed structural damage.11 In a 1-year, randomised, double-
blind study (N=60), no difference in erosive progression was 
seen after 12 months between groups who received adalimumab 
40 mg subcutaneously every 2 weeks or placebo. However, in a 
post-hoc analysis, adalimumab was associated with significantly 
less erosive progression than placebo in patients with joints with 
soft-tissue swelling.10 In two other randomised, double-blind 
studies, adalimumab did not improve pain and other outcomes 
compared with placebo.50 51 In a single-blind study, 10 patients 
received monthly injections of infliximab or saline into affected 
joints (opposite hands in each patient). After 12 months of treat-
ment, pain was significantly reduced by infliximab; radiographic 
lesion progression was reduced but not statistically different 
compared with saline.52 A 12-week, open-label study (N=12) 
with adalimumab suggested modest clinical efficacy.53
The strengths of the current study include its stringent enrol-
ment of only patients with moderate to severe inflammation and 
the measurement of efficacy, multiple imaging scoring systems, 
and pharmacodynamics in the same subjects. However, several 
inherent limitations may have affected the findings. More than 
26 weeks may have been needed to observe a structural effect of 
lutikizumab in patients with erosive HOA and to detect related 
pain and function improvement. Although pharmacodynamic 
measures such as the ANC suggest that IL-1 levels were maxi-
mally suppressed in the circulation by 200 mg of lutikizumab 
every 2 weeks,44 we did not measure hand joint synovial fluid 
levels of lutikizumab, IL-1α and/or IL-1β; therefore, IL-1α and 
IL-1β concentrations may not have been reduced locally in the 
joint to a level that improved pain and function or showed 
radiographic evidence of structural improvement. In addition, 
we have no adequate explanation for the low use of NSAIDs 
or analgesics, given the high average level of pain in patients at 
baseline.
In conclusion, despite adequate systemic lutikizumab phar-
macodynamic effects, lutikizumab did not significantly improve 
clinical outcomes or imaging outcomes in patients with erosive 
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HOA, compared with placebo, suggesting that targeting IL-1 
may be ineffective for the treatment of erosive HOA.
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